JAGX
Jaguar Health, Inc.
stockNASDAQ
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar's non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.82 | 2026-10-19 | -15.96% | -3.378 |
| 1M | 7.70 | 2026-09-25 | -69.22% | -4.624 |
| 3M | 15.00 | 2026-07-27 | -84.20% | -0.030 |
| 6M | 147.05 | 2026-04-27 | -98.39% | 1.202 |
| 1Y | 978.41 | 2025-10-27 | -99.76% | 2.342 |
| 2Y | 13,244.32 | 2024-10-25 | -99.98% | — |
| 5Y | 133,159,095.00 | 2021-10-26 | -100.00% | 1.527 |
Jaguar Health, Inc. (NASDAQ:JAGX) stock price today is $2.37, and today's volume is 2,039,670. JAGX is up 16.176% today. The 30 day average volume is 4.48M. JAGX market cap is $5.51M with 2.32M shares outstanding.